Antiviral Therapy in Pregnancy

Za, Brown; Dh, Watts

doi:10.1097/00003081-199006000-00010

Cited by 13 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is now clear that serial maternal antenatal cultures are not predictive of the development of neonatal herpes, and they are therefore not indicated [37,38].…”

Section: Mode Of Delivery For Maternal Recurrent Genital Herpesmentioning

confidence: 99%

Guidelines for the management of herpes simplex virus in pregnancy

2008

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…It is now clear that serial maternal antenatal cultures are not predictive of the development of neonatal herpes, and they are therefore not indicated [37,38].…”

Section: Mode Of Delivery For Maternal Recurrent Genital Herpesmentioning

confidence: 99%

Guidelines for the management of herpes simplex virus in pregnancy

2008

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Since then, their effectiveness and safety have been established in non-pregnant patients, but use in pregnancy has been prohibited due to several fetus-related issues. Acyclovir and zidovudine have only been used during pregnancy in case reports and pharmacokinetic investigations [ 312 ].…”

Section: Vaccines and Antiviral Therapy In Pregnancymentioning

confidence: 99%

Gestational Viral Infections: Role of Host Immune System

Beltrami,

Rizzo,

Schiuma

et al. 2023

Microorganisms

View full text Add to dashboard Cite

Viral infections in pregnancy are major causes of maternal and fetal morbidity and mortality. Infections can develop in the neonate transplacentally, perinatally, or postnatally (from breast milk or other sources) and lead to different clinical manifestations, depending on the viral agent and the gestational age at exposure. Viewing the peculiar tolerogenic status which characterizes pregnancy, viruses could exploit this peculiar immunological status to spread or affect the maternal immune system, adopting several evasion strategies. In fact, both DNA and RNA virus might have a deep impact on both innate and acquired immune systems. For this reason, investigating the interaction with these pathogens and the host’s immune system during pregnancy is crucial not only for the development of most effective therapies and diagnosis but mostly for prevention. In this review, we will analyze some of the most important DNA and RNA viruses related to gestational infections.

show abstract

“…A theoretical concern is whether symptomatic recurrences would be converted to asymptomatic shedding episodes by suppressive treatment, thus potentially increasing an infant's perinatal exposure to HSV through a vaginal delivery 12 . The reported incidence of asymptomatic HSV shedding at any given time in pregnant women with genital herpes is about 1-2% [13][14][15] .…”

Section: (30%)mentioning

confidence: 99%

Acyclovir Suppression to Prevent Recurrent Genital Herpesat Delivery

Scott

Hollier

McIntire

et al. 2001

Infectious Diseases in Obstetrics and Gynecology

View full text Add to dashboard Cite

OBJECTIVE: To determine if suppressive acyclovir near term decreased the frequency of clinical recurrences at delivery in women with recurrent genital herpes simplex virus (HSV) infection. METHODS: We conducted a prospective, double-blind, randomized trial in 234 women with recurrent genital herpes. Women with genital infection of any frequency were enrolled. Patients received either suppressive oral acyclovir 400 mg three times daily or an identical placebo after 36 weeks' gestation. Clinical lesions were identified, and HSV cultures were obtained at delivery. The frequencies of clinical and subclinical HSV recurrences at delivery were evaluated. RESULTS: Six percent of patients treated with acyclovir, and 14% of patients treated with placebo had clinical HSV at delivery (p = 0.046). No patients in the acyclovir group had positive HSV cultures, compared with 6% of placebo-treated patients (p = 0.029). There was no significant difference in subclinical HSV shedding in the acyclovir group (0%) compared with the placebo-treated group (3%) (p = 0.102). CONCLUSIONS: Suppressive acyclovir therapy significantly decreased the incidence of clinical genital herpes and the overall incidence of HSV excretion at delivery in patients with previous herpes infection.

show abstract

Antiviral Therapy in Pregnancy

Cited by 13 publications

References 0 publications

Guidelines for the management of herpes simplex virus in pregnancy

Guidelines for the management of herpes simplex virus in pregnancy

Gestational Viral Infections: Role of Host Immune System

Acyclovir Suppression to Prevent Recurrent Genital Herpesat Delivery

Contact Info

Product

Resources

About